The latest financial statement is for the quarter ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Net loss | -313,701 | -166,039 | -273,911 | -252,375 |
| Non-cash acquired in-process research and development | - | - | - | 0 |
| Share-based compensation | 104,997 | 81,821 | 82,178 | 83,488 |
| Change in fair value of investments | 21,592 | 128,501 | -19,125 | 12,899 |
| Change in fair value of debt and liability instruments | -24,416 | -20,959 | -2,329 | 14,124 |
| Gain on sale of subsidiary interests | 0 | - | - | 0 |
| Gain on deconsolidation of subsidiaries | - | - | - | 3,108 |
| Gain on sale of telavant net assets | 0 | 0 | 0 | 0 |
| Gain on recovery of contingent consideration | - | - | - | 0 |
| Impairment loss on operating lease right-of-use assets | 15,594 | - | - | - |
| Accretion of discount and amortization of premium on marketable securities, net | 8,723 | 9,822 | 11,061 | 15,655 |
| Realized gain from sales of marketable securities | 347 | - | - | - |
| Loss on extinguishment of debt | 0 | - | - | 0 |
| Depreciation and amortization | 691 | 921 | 1,098 | 1,425 |
| Non-cash lease expense | 2,527 | 1,942 | 1,943 | 1,972 |
| Other | 9,718 | -5,980 | -11,082 | -4,227 |
| Other current assets | 2,733 | 4,390 | -128 | -28,852 |
| Other assets | - | - | - | 8,758 |
| Accounts payable | -3,988 | 2,996 | -11,745 | -165 |
| Accrued expenses | 8,580 | 12,520 | -25,000 | 9,437 |
| Operating lease liabilities | -786 | -846 | -478 | -241 |
| Accrued interest | - | - | - | 0 |
| Other liabilities | - | - | - | -9,280 |
| Other | -8,299 | 3,205 | -14,568 | - |
| Net cash used in operating activities | -196,484 | -185,664 | -204,383 | -172,565 |
| Purchases of marketable securities | 1,013,713 | 976,730 | 1,801,681 | 0 |
| Proceeds from sale of myovant top-up shares | - | - | - | 0 |
| Proceeds from maturities of marketable securities | 2,745,000 | - | - | - |
| Milestone payments | - | - | - | 0 |
| Maturities of marketable securities | - | 1,105,000 | 720,000 | 1,000,000 |
| Proceeds from sales of marketable securities | 200,766 | - | - | - |
| Purchase of property and equipment | -4,935 | 7,848 | 4,035 | 811 |
| Proceeds from sale of subsidiary interests | 0 | 0 | - | 75,000 |
| Proceeds from sale of telavant net assets, net | 0 | - | - | 0 |
| Cash decrease upon deconsolidation of subsidiaries | 0 | - | - | 74 |
| Other | 2,518 | - | - | -79 |
| Proceeds from issuance of the company's common shares, net of issuance costs paid | - | - | - | 0 |
| Net cash used in investing activities | 109,470 | 120,422 | -1,085,716 | 1,074,194 |
| Proceeds from issuance of subsidiary common shares, net of issuance costs paid | 193,605 | - | - | 112,782 |
| Proceeds from subsidiary debt financings, net of financing costs paid | - | - | - | 0 |
| Contribution from minority interest holder to subsidiary | 39,250 | - | - | - |
| Repayment of debt by subsidiary | 0 | 0 | 0 | 0 |
| Payment of offering costs and loan origination costs | - | - | - | 0 |
| Payments on principal portion of finance lease obligations | 0 | 0 | 0 | 0 |
| Proceeds from exercise of the companys and subsidiary stock options | 118,814 | 68,294 | 30,057 | 12,591 |
| Payment of subsidiary dividend | - | - | - | 0 |
| Taxes paid related to net settlement of equity awards | 23,856 | 6,481 | 9,532 | 7,461 |
| Proceeds from exercise of the company's warrants | - | - | - | 0 |
| Repurchase of the companys common shares | 0 | 0 | 208,293 | 295,445 |
| Payment for redemptions of the company's warrants | - | - | - | 0 |
| Proceeds from issuance of the companys common shares under employee stock purchase plan | 381 | 774 | - | 380 |
| Net cash provided by (used in) financing activities | 328,194 | 62,587 | -187,768 | -177,153 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 430 | 1,206 | 815 | -489 |
| Net change in cash, cash equivalents and restricted cash | 241,610 | -1,449 | -1,477,052 | 723,987 |
| Cash and cash equivalents at beginning of period | 1,247,160 | 1,248,609 | 2,725,661 | 2,001,674 |
| Cash and cash equivalents at end of period | 1,488,770 | 1,247,160 | 1,248,609 | 2,725,661 |
Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (ROIV)